Efectividad y seguridad de los nuevos anticuerpos monoclonales en la profilaxis de la migraña

Carvajal-Sánchez, M A; Nájera-Pérez, M. D; Plaza-Aniorte, J; Hernández-Sánchez, M; Pacheco-López, P; León-Villar, J.
O.F.I.L ; 34(1): 67-71, 2024. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-232625

Documentos relacionados

  1. Yoga for Migraine Prevention: An Ancient Practice with Evidence for Current Use.
  2. The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
  3. Neuroscience Education as Therapy for Migraine and Overlapping Pain Conditions: A Scoping Review.
  4. Update of Neuromodulation in Chronic Migraine.
  5. Modeling and visualizing two-way contingency tables using compositional data analysis: A case-study on individual self-prediction of migraine days.
  6. Migraine - Patient Perspectives.
  7. Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine.
  8. Synthesis of a dual carbon-14-labeled calcitonin gene-related peptide receptor antagonist for use in a human absorption-distribution-metabolism-elimination study.
  9. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
  10. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.